A pragmatic approach that balances the benefit of a whole-genome association (WGA) experiment against the cost of individual genotyping is to use pooled genomic DNA samples. We aimed to determine the feasibility of this approach in a WGA scan in rheumatoid arthritis (RA) using the validated human leucocyte antigen (HLA) and PTPN22 associations as test loci. A total of 203 269 single-nucleotide polymorphisms (SNPs) on the Affymetrix 100K GeneChip and Illumina Infinium microarrays were examined. A new approach to the estimation of allele frequencies from Affymetrix hybridization intensities was developed involving weighting for quality signals from the probe quartets. SNPs were ranked by z-scores, combined from United Kingdom and New Zealand case-control cohorts. Within a 1.7 Mb HLA region, 33 of the 257 SNPs and at PTPN22, 21 of the 45 SNPs, were ranked within the top 100 associated SNPs genome wide. Within PTPN22, individual genotyping of SNP rs1343125 within MAGI3 confirmed association and provided some evidence for association independent of the PTPN22 620W variant (P ¼ 0.03). Our results emphasize the feasibility of using genomic DNA pooling for the detection of association with complex disease susceptibility alleles. The results also underscore the importance of the HLA and PTPN22 loci in RA aetiology.
Introduction
Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease caused by inflammation of synovial tissue. Although it clearly has a genetic basis, 1 the genetic causes of RA remain poorly defined. Until now, most insight into genetic aetiology has come from the study of functional candidate genes. Genetic association with alleles of the class II antigen-presenting molecule human leucocyte antigen (HLA)-DRB1 on chromosome 6p has been established for decades (odds ratio (ORs) ¼ 2.5-3.0), with the shared epitope, defined mainly by subtypes of DRB1*04 and *01, prominent in Caucasians. 2 Recently, the 620W allele of the PTPN22 gene (which encodes the lymphoid tyrosine phosphatase), has been confirmed as a determinant of RA by extensive replication of association in Caucasian patient cohorts. 3 Other genes are implicated in RA susceptibility, with CTLA4 and PADI4 the closest to being 'confirmed', 4, 5 although their effect (OR ¼ 1.1-1.3) is less than that of PTPN22 (OR ¼ 1.5-2.0).
Microarray-based technology to enable whole-genome scanning for association (WGA) has evolved to the point where this approach to elucidating the genetic basis for common disease has become feasible. [6] [7] [8] By the simultaneous genotyping of hundreds of thousands of singlenucleotide polymorphisms (SNPs) using the widely available Affymetrix and Illumina technologies, WGA scanning offers the promise of disease gene discovery through linkage disequilibrium (LD) to causal DNA changes. Although the optimal study design for a WGA experiment is a matter for debate, identification and validation of the genes encoding complement factor H, insulin-induced gene 2 and interferon-induced helicase as determinants of age-related macular degeneration, body mass index and type 1 diabetes, respectively, 9-11 do provide confidence that this approach can be widely applied to complex disease. Whole-genome association studies can be very expensive if case-control or family-based cohorts of a 1000 or more subjects are individually genotyped. This is likely to limit the number of primary discovery experiments that can be conducted. A pragmatic approach that balances the benefit of a WGA experiment against the cost of individual genotyping is to use pooled genomic DNA samples, followed by individual genotyping for validation in an expanded or independent sample. 12, 13 Pooled DNA samples have been analysed for several generations of DNA-based genetic markers such as microsatellite and candidate SNPs using several technologies, including using the Affymetrix GeneChip Mapping 100K Array. [14] [15] [16] [17] [18] [19] [20] To date, however, the empirical validity of DNA pooling and genotyping using array technology has not been sufficiently demonstrated to enable researchers to apply the method with confidence in WGA experiments.
Here our aim was to investigate whether DNA pooling was an effective approach for a WGA study in an empirical setting with the Affymetrix GeneChip Mapping 100K and Illumina Infinium microarray platforms with specific testing for association of the established HLA and PTPN22 loci with RA. To maximize accuracy of pooled allele frequency estimates (and hence power of WGA scanning) using the Affymetrix GeneChip Mapping 100K Array, a novel algorithm to account for the quality of individual probe quartets was developed. We also improved our WGA scan by overlapping analysis of pools of case-control cohorts from two racially and clinically similar populations (Caucasians from New Zealand (NZ) and the United Kingdom (UK)).
Results
Forty different sets of pooled samples were run on Affymetrix 100K GeneChip microarrays (data not shown). Data from replicate microarrays were compared and the median standard deviation (s.d.) in allele frequency was 2.9%, in comparison to 7.4% using the Affymetrix algorithm (based on averaging relative allele signal (RAS) 1 (sense probes) and RAS 2 (antisense probes) values). The median s.d. in allele frequency obtained from comparison of data obtained from running 14 different sets of pooled samples on replicate Illumina Infinium microarrays was similar at 2.7% (data not shown).
In order to evaluate how well allele frequency could be estimated from a pool, 39 individually typed Centre d'Etude du Polymorphisme Humain (CEPH) samples were pooled and genotyped across an Affymetrix 100K GeneChip microarray. Figure 1 shows the relationship between minor allele frequencies calculated from the pool and actual frequencies derived from the individually typed samples for 200 randomly selected SNPs. The median absolute difference between the corresponding frequencies was 3.1% and mean dispersion 3.4%. The median s.d. of predicted allele frequency for the same CEPH pool run on four different chips was 3.2%.
In order to compare the ability to detect association using our DNA pooling approach with the ability to detect association based on individual genotyping, a data set of 250 cases and 250 matched controls was considered. Assuming that two pools, one for cases and one for controls, were run on four replicate microarrays each, we were able to estimate s.d. for the typical SNP (see Patients and methods, Detection of association). We defined the minimal detectable difference in allele frequency (MDDAF) as an expected (in infinitely large data sets) allele frequency difference between cases and controls at which power to detect association is 80% as Df ¼ z*s, where z* is a threshold value for a z-score to detect association. Assuming that an association is detected whenever a P-value is below P ¼ 4 Â 10 À5 (z*B4.13) and s 0 ¼ 0.028, we calculated MDDAF as a function of minor allele frequency. Figure 2 shows the loss in ability to detect allele frequency differences using DNA pooling compared to individual genotyping. This loss appears to be acceptable. Figure 2 Ability to detect association using the DNA pooling approach. The MDDAF is plotted as a function of minor allele frequency at a significance level P ¼ 0.001.
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We then performed a WGA scan in RA and specifically examined association at two loci previously unambiguously associated with RA. If association at HLA and PTPN22 could be detected using DNA pooling, this would be empirical demonstration of efficacy of this technique in WGA analysis in RA genetics and would warrant later examination of the entire genome for novel disease-associated loci. NZ and UK case and control pools were hybridized, in quadruplicate, to Affymetrix 100K GeneChip and Illumina Infinium microarrays and a combined z-score determined for all SNPs. The estimated allele frequencies, z-scores and genome-wide ranks of SNPs within the class II/III HLA and PTPN22 windows are presented in Tables 1 and 2 , respectively. The maximal z-score at HLA was 5.554 (P ¼ 3 Â 10
À8
) and at PTPN22 was 5.511 (P ¼ 4 Â 10
). Both of these remain significant after correcting for the total number of SNPs analysed (P c o0.01).
At HLA, a total of 33 SNPs (representing 18 'unique hits' after exclusion of SNPs exhibiting complete intermarker LD with at least one other SNP) were ranked within the top 100 associated SNPs genome wide from both the Affymetrix and Illumina microarrays (Table 1) . HapMap CEPH CEPH Utah (CEU) genotyping data were available on 181 of the 257 HLA SNPs on the microarrays and the LD relationships between these are shown in Figure 3 . Twenty-six of the diseaseassociated SNPs (for 15 of which Hapmap data were available) were clustered within four closely related LD blocks encompassing the predicted gene C6orf10, BTNL2 and HLA-DRA. These blocks are defined by HapMap markers rs9296015-rs3129941 (blocks 9-10, Figure 3) , and rs2076530-rs1041885 (blocks 11-12, Figure 3 ). Outside the C6orf10 and HLA-DR regions, seven other SNPs (for which Hapmap data were available on six) within the major histocompatibility complex class III region provided evidence for association. Six of these were clustered around the complement component C2 (rs3020664, rs1042663 and rs541862), complement factor B, RD RNA binding protein (rs760070) and superkiller viralicidic activity 2-like homologue (rs438999) loci, of which four exhibited strong intermarker LD (r 2 40.75; LD block 4 in Figure 3 ). The seventh, rs9296009, is intergenic and lies approximately 2.5 kb p-telomeric of proline-rich transmembrane protein 1. The minor allele is indicated in brackets.
Inspection of LD in the CEPH CEU families did not identify any SNP markers that were in strong LD with the known associated HLA-DRB1*0401 allele. The topranked Affymetrix 100K GeneChip SNP was one of the markers closest to HLA-DRA (rs9268614), 155 kb from HLA-DRB1, that exhibited some LD with HLA-DRB1*0401 in the CEPH CEU individuals (r 2 ¼ 0.26). The extended NZ cohort was individually genotyped for rs9268614 and we tested for the possibility of an effect independent of HLA-DRB1*04. Association was confirmed, with allele G occurring at a significantly higher frequency in cases than controls (Table 3a ; P ¼ 5.4 Â 10
À15
). This SNP was in LD with DRB1*04 alleles (r 2 ¼ 0.49 in NZ controls and 0.66 in the NZ extended case cohort). Conditional analysis of rs9268614 on the presence of DRB1*04 alleles showed weak evidence for independent association (P ¼ 0.02). Analysis of haplotypes between rs9268614 and the DRB1*04 allele revealed 
org).
Genomic DNA pooling for WGA S Steer et al global association (P ¼ 4.4 Â 10 À30 ) and confirmed the major effect of the presence or absence of the DRB1*04 allele.
At PTPN22, 21 SNPs (representing seven 'unique hits' after exclusion of SNPs exhibiting complete intermarker LD with at least one other SNP) were ranked within the top 100 associated SNPs genome wide (Table 2) . LD relationships between the associated SNPs for which HapMap CEPH CEU genotyping data were available are shown in Figure 4 . These data suggest that the PTPN22 Figure 3 Intermarker LD between SNPs within the class II and class III HLA window. Only those SNPs contained on the Affymetrix 100K GeneChip and Illumina Infinium microarrays and for which CEPH CEU genotype data were available are shown. SNPs ranked in the top 100 are arrowed. Haplotype blocks (n ¼ 22) generated in Haploview (www.broad.mit.edu/mpg/haploview) are outlined by a solid black line. Block numbers referred to in the text are from left to right. Horizontal lines indicate genes; A ¼ C2/CFB/RDBP/SKIV2L, B¼ PPRT1, 
org)).
Genomic DNA pooling for WGA S Steer et al 620W variant is the major disease-causing allele in the extended haplotype block; there was correlation between amount of LD with the R620W variant (rs2476601) and z-score (correlation coefficient ¼ 0.64). Four of the disease-associated SNPs (rs1343128, rs1418958, rs1343125 and rs1217201) were clustered at the telomeric end of the region within the membrane-associated guanylate kinase-related 3 (MAGI3) gene. Although it is possible that the association at the MAGI3 SNPs is due to LD with the PTPN22 620W variant (Figure 4 ), given the presence of a disease-associated haplotype in US Caucasians that is independent of PTPN22 620W 21 we hypothesized that the MAGI3 SNPs themselves, or variants in LD, defined a disease-association distinct to the 620W association. The MAGI3 SNP rs1343125 was genotyped across the extended NZ RA case-control cohort. This confirmed association of the C allele with disease (Table 3a ; P ¼ 1.8 Â 10 À4 ). Disease association of rs1343125-R620W haplotypes was then analysed (Table 3b ). The T allele at rs1343125 was present on a protective haplotype with the 620R allele (OR ¼ 0.68; P ¼ 1.3 Â 10
À5
) whereas there was weak evidence for over-representation of the C-620R haplotype in cases compared to controls (P ¼ 0.05). Association analysis at rs1343125 conditional on PTPN22 R620W also provided evidence for an effect independent of PTPN22 R620W (P ¼ 0.03).
Discussion
This paper reports methodology for WGA scanning in complex disease using pooled genomic DNA samples and the Affymetrix 100K GeneChip and Illumina Infinium microarray platforms. The empirical efficacy of the method for detecting loci of moderate to strong effect in complex disease was demonstrated by detection of the HLA and PTPN22 loci in RA (OR41.5). Our data emphasize the importance of the HLA and PTPN22 loci (relative to the rest of the genome) in the aetiology of RA. Using control population allele frequencies of 0.19 for HLA-DRB1*04 and 0.099 for PTPN22 R620W, and genotype relative risk estimates from the extended NZ RA cohort, the estimated population attributable risk 22 for each locus was 41.7 and 11.4%, respectively. Considering that the environment also contributes to the aetiology of RA it is unlikely that more than several other genetic variants of effect greater than PTPN22 R620W remain to be discovered. Of course, it is most important to acknowledge that the genotyping platforms used here tag, at r 2 X0.8, only approximately 50% of common variation in the human genome in Caucasians. 23 However, an association analysis of 46500 nonsynonymous SNPs (nsSNPs) has also emphasized the importance of PTPN22 R620W in autoimmunity; 11 this nsSNP was the most associated with type I diabetes outside HLA.
The use of DNA pooling has potential as an extremely cost-effective method to identify a reduced set of potentially disease-associated SNPs suitable for follow-up in the second phase of a WGA experiment. The key to using DNA pooling in WGA scanning is reducing variability in estimation of allele frequency in genomic DNA pools. Given the current wider use and longer availability of the Affymetrix GeneChip Mapping 100K Array, we focused on developing an improved algorithm able to minimize variation in estimation of allele frequencies in DNA pools. Previous methods have improved the Affymetrix algorithm by averaging the RAS scores corresponding to each of the sense and antisense probe sets, applying the k Genomic DNA pooling for WGA S Steer et al correction factor (often used in pooling experiments to correct for unequal efficiencies in measuring allele signals 24 ) and repeated measurement of DNA pools. 19, 25, 26 The fundamental difference between our and previous algorithms for estimating allele frequencies in DNA pools using the Affymetrix GeneChip Mapping 100K Array 19, 26 is in calculation of RAS scores for each SNP. The Affymetrix algorithm obtains RAS as a median value from five quartet sense (RAS1) and five quartet antisense (RAS2) sequences (containing match and mismatch SNP probes). For most SNPs, this is sufficient to distinguish between homozygous and heterozygous genotypes in analysis of individual samples. 6 However, the s.d. of the estimated allele frequency in pooled samples using the Affymetrix algorithm (7.4%) is simply too great to apply to WGA scanning. To address this, we calculated all 10 RAS scores (corresponding to the five sense and five antisense probe quartets) and summed these scores weighted with coefficients that were inversely proportional to the square of their variability. The s.d. of the difference in allele frequency between pools of cases and controls consists of two components, the first coming from the limited size of the pools and the second from imprecise measurement of the allele frequency in the pool (see above). Although the s.d. will always decrease with increasing number of pooled samples it cannot become lower than its second component. Thus the power of the study will quickly plateau after the size of the pools becomes sufficiently large for the second component of the s.d. to become larger than the first. Such conditions will be obtained for pools with B400 samples for Affymetrix 100K chips and with B550 samples for Illumina 100K chips. In our study, the NZ case pool approaches the optimal sample size for the Affymetrix chip, but other sample sizes would need to be increased to improve power to detect loci with statistically smaller effects than PTPN22. The approach of combining data from the NZ and UK cohorts also reduced the noise in the WGA scan data observed when the cohorts were analysed separately ( Figure 5) ; the HLA and PTPN22 associations are considerably more obvious when the cohorts are analysed together (Figure 5b and d) than separately (Figure 5a and c) .
For several reasons, if economic considerations are not central to the design of a WGA study, individual genotyping is preferable to estimation of allele frequencies by DNA pooling. This is because the use of DNA pooling does not enable the detection and controlling of population stratification, and there is the loss of ability to study haplotypes and to undertake gene-gene interaction studies. However, if cost is an impediment then this DNA pooling methodology will enable WGA 21 identified one disease-susceptibility PTPN22 haplotype (haplotype '2', uniquely defined by the 620W allele) and one disease-protective haplotype in US Caucasians (haplotype '5'). Our data confirm the existence of a disease-protective haplotype in NZ Caucasians -the T allele of the MAGI3 SNP rs1343235 in combination with PTPN22 620R defined a protective haplotype (Table 3b ; P ¼ 1.3 Â 10
À5
). Our data also provide evidence that there is an additional risk haplotype, carrying the rs1343125 risk C allele with the protective PTPN22 620R allele. Combined with the analysis of association of rs1343125 conditional on genotype at R620W (P ¼ 0.03), these findings are evidence of a second RA locus in the extended PTPN22 haplotype block (Table 3b ). MAGI3 can be considered a candidate RA susceptibility gene; MAGI3 associates with the Notchactivating Delta proteins 27 and NOTCH signalling has been implicated in the pathophysiology of RA. 28 The possibility of a RA susceptibility determinant elsewhere in the PTPN22 haplotype block is further supported by the observation that the haplotype '5'-defining PTPN22 SNP rs12760457
21 is in complete LD with four MAGI3 SNPs (Figure 4 ; rs10489936, rs3761931, rs3747998 and rs1080307). None of these SNPs were associated with RA in our study (Table 2 ; z ¼ 0.84 for the SNPs on the Affymetrix 100K GeneChip chip and z ¼ 0.69 for the SNPs on the Illumina Infinium chip). There is, however, a group of SNPs within PHTF1 (putative homeodomain transcription factor 1) and the 3 0 end of PTPN22 (rs2273758, rs3789598, rs3789600 and rs2476600) that are in moderate LD (0.3or 2 o0.4) with the four MAGI3 SNPs and rs12760457, and for which there is stronger evidence for association with RA (3.1ozo4.2). These PHTF1/ PTPN22 SNPs exhibit low LD with PTPN22 R620W (rs2477601) (r 2 p0.2). These WGA data do indicate that further analysis of the PTPN22 region is warranted; understanding the relationship of these SNPs with the protective haplotype '5' previously identified 21 should be most informative in identifying a possible second RA susceptibility determinant in the PTPN22 region.
The HLA region, and to a lesser extent the PTPN22 locus, dominated the top-ranked SNPs (Tables 1 and 2 ). This is atypical in the context of other WGA scans. 9, 10, 29 PTPN22 maps within an unusually large block of extended LD (4300 kb) that contains several other genes. This large haplotype block, combined with the selection of gene-centric SNPs on the Illumina Infinium microarray 7 goes some way to explaining the number of topranked PTPN22 SNPs in our WGA data. Dominance of SNPs in the HLA region is less surprising, given previous evidence for the existence of multiple RA susceptibility loci in this region. The HLA region was one of the top seven regions detected as associated with RA in Japanese as a result of the WGA genotyping of microsatellites over pooled genomic DNA samples. 30 The strongest associated HLA SNP was the 41st ranked Affymetrix SNP in our genome-wide scan (rs2227139) and maps within the same HLA-DRA-containing block of LD (32489917-32521295 Mb) as the highest ranked Affymetrix SNP (rs9268614) in our WGA scan. This block is flanked by the BTNL2 and HLA-DRB3 loci, as well as C6orf10 (for which no transcripts have been identified to date). Several previous studies have reported associations in the telomeric class III region, independent of HLA-DRB1, particularly centred on the lymphotoxin a, and tumour necrosis factor-a loci. [31] [32] [33] [34] [35] Our WGA scan data did not provide evidence for association with RA of SNPs in this region (all zo0.8), but did demonstrate association with SNPs in and around loci encoding components of the complement pathway, complement component C2 and complement factor B. Previous studies that have demonstrated association in and around these loci have not been able to consistently show that association is independent of the HLA-DRB1*04 haplotype. 36, 37 However, taken together, data generated by us and others [30] [31] [32] [33] [34] [35] 38, 39 strongly suggest multiple RA susceptibility loci within the HLA region, with the HLA class II association the strongest. A comprehensive HLA SNP genotyping experiment is warranted in RA, using sufficiently large cohorts to enable detection of effects independent of HLA-DRB1.
We have empirically demonstrated that a WGA scan using DNA pooling and combination of data from independent cohorts is an effective method for detecting association at a genome-wide level of significance to complex disease loci of relatively large effect. However, additional strategies will be needed to enable detection of genuine association to loci situated in regions of lower LD than PTPN22 (which would have lower numbers of associated SNPs) and to loci of weaker effect (OR 1.2-1.5. e.g. CTLA4, PADI4). Lowering the threshold of significance for selection of SNPs for follow-up analysis may be necessary for SNPs within functionally relevant genes and genes mapping within areas of linkage to disease. This can be achieved using the false-discovery rate (FDR) principle, which maximizes power by controlling the fraction of false rejections rather than the type I error rate. An FDR approach for weighting WGA scan Pvalues on the basis of previous linkage data has been proposed. 40 Finally, replication of putative associations to loci of weak effect will be vital in additional cohorts of large size. Guidelines for conducting WGA scans have been published. 41 However it is likely that optimal strategies for novel disease gene discovery using WGA scanning will be refined in an empirical process, of which this study and others 9, 20, 29 represent the first steps. The use of DNA pooling should facilitate development of these WGA scanning strategies.
Patients and methods

Clinical samples
The NZ cohort consisted of 384 (268 females and 116 males) patients and 296 healthy controls (148 females and 148 males) and the UK cohort of 241 (184 females and 57 males) patients and 262 healthy controls (116 females and 146 males). All patients satisfied the American College of Rheumatology criteria for the classification of RA. 42 Clinical characteristics for the cohorts are (NZ/UK, 7s.d.); 69.4/76.3% females, 42.7714.5/ 48.3713.5 years of age at onset, 17.679.0/13.5710.8 years disease duration, 81.7/64.7% rheumatoid factor positive and 82.1/77.2% positive for the shared epitope. 2 Ethical approval for the study in NZ was given by the Otago ethics committee (as lead committee), and in the UK by the Lewisham Hospital and Guy's and St Thomas' Hospitals local research ethics committees. All subjects were white Caucasian and gave written informed consent.
Genomic DNA preparation and pooling The NZ genomic DNA samples were all prepared from white blood cells pelleted from whole blood using a standard Gu-HCl-based white blood cell lysis and chloroform extraction protocol; the UK case genomic DNA samples were all extracted using a standard TrisHCl-based white blood cell lysis and phenol/chloroform extraction protocol, and the UK control genomic DNA samples were extracted from immortalized cell lines using Qiagen spin column separation technology. DNA samples were electrophoresed on agarose gels and samples with intact genomic DNA showing no smearing on agarose gel electrophoresis were selected for pooling. Intact genomic DNA was diluted to 50 ng/ml concentration based on Quant-iT Picogreen (Invitrogen, Eugene, Oregen) quantitation and then concentration confirmed by repeating the picogreen analysis. Concentrations were adjusted based on these results and then picogreen analysis was repeated. This process was repeated until all samples consistently measured 50 ng/ml. Pools were constructed by combining equal volumes of each DNA. All pipetting steps were of volumes greater than 2 ml to minimize pipetting error. Four replicates from each pool were prepared and hybridized to Affymetrix GeneChip Mapping 100K Array and Illumina Infinium microarrays according to the manufacturers protocols.
Estimation of pooled allele frequency using Affymetrix GeneChip mapping 100K array A new approach was developed to estimate allele frequency by combining hybridization intensities for each SNP from the 10 different oligonucleotide probe quartets consisting of perfect-match (PM) and mismatch (MM) pairs for both alleles (five in the sense direction and five in the antisense direction). In the current version of the Affymetrix algorithm, signals from perfectly matched probes are adjusted on the signal from mismatched probes: These RAS values allow clear distinction between homozygous and heterozygous genotypes for the majority of SNPs. However there are three reasons (A, B and C) why they do not provide a sufficiently accurate estimate of average allele frequency among pooled samples. A: Not all RAS values for the same SNP are equally good for determination of allele frequency (e.g., some of them might have higher noise level than others). B: RAS values are always between 0 and 1, which makes distribution of RAS values different from normal for homozygous genotypes in individual samples and for SNPs with low allele frequency in pools. In particular, variation of RAS values for homozygous calls is artificially reduced. This creates bias towards higher heterozygosity (average RAS values even for homozygous calls appear to be higher than 0 and lower than 1) and makes any further statistical analysis difficult. C: The intensity of fluorescence of different alleles is not necessarily equal, creating bias in overestimation of the frequency of the allele with higher expression. In our analysis we addressed these problems in order to decrease the s.d. First of all, we slightly changed the definition of RAS values:
This change allows RAS to be o0 and 41 thus eliminating bias towards higher heterozygosity and resolving problem B (we tried to exclude averaged mismatch signal MM from the above equation but we found that precision in estimation of allele frequency decreased for the majority of SNPs (data not shown)). We started by genotyping 94 individual CEPH samples. Then for each quartet we calculated the median RAS values for genotypes AA, AB and BB (RAS AA , RAS AB and RAS BB ). We used median values rather than mean to decrease effect of outliers. For simplicity we assume in our further explanations that RAS AA XRAS AB XRAS BB . To estimate the average allele frequency among pooled samples linear interpolation was first used to calculate the frequency of allele A based on the data from each quartet. If in the pool RASXRAS AB the following equation was used to estimate allele frequency:
If RAS AB XRAS the following equation was used instead:
This approach allowed minimization of the bias from problems B and C. After that we combined these frequencies with weights reflecting the quality of the corresponding RAS values, which allowed resolution of problem A:
where the sum is over q ¼ 1 to 10 and w q is a weight for quartet q. To determine these parameters we used genotyping data of the individually typed CEPH samples (with the 0.25 quality parameter cutoff the average call rate for the Affymetrix Xba chip was 97.8 and 96.8% for the Hind chip). Each individually genotyped sample s can be considered as a pool consisting of a single sample. The allele frequency f s in this pool is fully determined by the individual's genotype: f s ¼ 1 for the AA genotype, f s ¼ 0.5 for the AB genotype and f s ¼ 0 for the BB genotype. In order to determine optimal weights w q for quartets, we minimized the differences between predicted allele frequencies f ¼ P q w q f q and known frequencies f s . More precisely, the following expression over w q was minimized:
where s denotes individually genotyped samples (s ¼ 1, y, n), and f s is 0, 0.5 or 1.0 according to the genotype of the individual.
Estimation of pooled allele frequency using the Illumina Infinium array A similar approach was used to estimate average allele frequency among pooled samples using the Illumina Infinium array. 
SNPs in LD Estimated allele frequencies for SNPs in total LD were averaged with weights based on their performance:
where s i 2 is the SNP-specific s.d. of the allele frequency estimation, f i is the estimate of allele frequency of one of the group of SNPs in LD, and f 0 is the averaged estimate of allele frequency for this group of SNPs.
Exclusion of SNPs from analysis
Of the 116 204 Affymetrix GeneChip Mapping 100K Array SNPs, 15.35% were excluded from analysis on the basis of not being informative in the CEPH samples (12.69%), location in duplicated regions (0.27%; whereby there was a 100% match of the 50 surrounding bases to two different positions within the human genome), deviation from Hardy-Weinberg equilibrium (HWE) (1.19%; Po1 Â 10 À5 ), and poor performance in estimating pooled allele frequency in CEPH individuals (1.20%; difference 412%). In the case of the Illumina Infinium array, 4.08% of the 109 365 SNPs were excluded from analysis on the basis of not being informative (4.07%) or presence in duplicated regions (0.01%) (insufficient Caucasian CEPH samples were genotyped to obtain data on SNPs deviating from HWE or performing poorly in allele frequency estimates from genomic DNA pools).
Differential bias in genotype scoring between case and control cohorts can arise when DNA samples originate from different laboratories; this was observed using the MegAllele (ParAllele BioScience) technology, with the authors having no reason to believe that the differential bias phenomenon is specific to this genotyping platform. 44 The possibility of this occurring is unlikely with our method -all SNPs with a high 'half-call' rate that contribute to this phenomenon 44 would be excluded from further analysis owing to high s.d.
Detection of association
The difference in allele frequency between pools was expressed as a z-score:
where f cases is the frequency of a SNP allele in cases, f controls is the same in controls and s is the s.d. which consists of two parts:
The first part of the total s.d., s s 2 , represents a sampling error owing to the limited number of cases and controls, and is the only error in the situation where cases and controls are genotyped individually and can be expressed as: where n cases and n controls are the numbers of microarray replicates for pools of cases and controls (for these studies n cases ¼ 4 and n controls ¼ 4), respectively, and s 0 2 is the SNP specific s.d. of the allele frequency estimation. Under the null hypothesis of no association, the z-score is normally distributed with mean ¼ 0 and variance ¼ 1. Therefore a z-score can be translated into a significance level expressed as a P-value.
Composite z-scores were calculated in four steps (A-D).
Step A. For each study SNPs were ordered according to their z-score (z-score1 UK , z-score1 NZ ) and corresponding rank numbers assigned to each SNP.
Step B. P-values were then calculated for each SNP to attain the given rank in each study: P i ¼ R i /N where R i is rank of SNP i and N is the total number of SNPs. After that we converted these P-values back to z-scores (z-score2 UK , z-score2 NZ ) assuming a normal distribution.
Step C. For each SNP with the allele frequency in cases lower than in controls, z-score3 ¼ Àz-score2. Otherwise, z-score3 ¼ z-score2.
Step D. The composite z-score was calculated as |z-score3 UK þ z-score3 NZ |/O2. Composite z-scores were obtained from Illumina Infinium-derived allele frequency estimates by applying Steps C and D only, whereas Steps A-D were applied to Affymetrix 100K GeneChip-derived allele frequency estimates because strong fluctuations in signal intensity in some SNPs led to deviation from the normal distribution of original z-scores. Therefore Steps A and B were added to enforce a Gaussian (normal) distribution of z-scores. Unfortunately, this also decreased the power of our method, weakening the effect from genuinely disease-associated SNPs whose z-scores do not fall in a Gaussian distribution.
Target regions examined
For PTPN22, analysis was limited to SNPs within a large conserved haplotype block of B365 kb (113.800-114.165 Mb), which contained all of PTPN22 (114.004-114.127 Mb). In the case of the HLA region, analysis extended to the most centromeric class II locus (DPA3). The HLA class II and III physical window was 31.500-33.207 Mb. Between the Affymetrix GeneChip Mapping 100K and Illumina Infinium arrays there were 257 SNPs included in the analysis within the HLA window (60 SNPs on the Affymetrix GeneChip Mapping 100K array and 202 SNPs on the Illumina Infinium array, five of these SNPs appeared on both arrays) and 45 within the PTPN22 window (11 SNPs on the Affymetrix GeneChip Mapping 100K array and 35 SNPs on the Illumina Infinium array, one of these SNPs appeared on both arrays). Haplotype block structure and intermarker LD relationships were inferred from CEU Caucasian data available from HapMap (www.hapmap.org).
Individual genotyping
Individual genotyping was carried out for the HLA rs9268614 and MAGI3 rs1343125 SNPs over 869 NZ cases and 563 controls (the same cohort genotyped with rs2476601 (PTPN22 R620W 45 ) using PCR-RFLP. For rs9268614 PCR with primers ACACGGGCCATGA AGGAATCTGAA and GTTGAAGGCAGGAATGAG TGTGGT created a 229 bp product that was cleaved by HhaI into 150 and 79 bp products in the presence of the G allele. For rs1343125 PCR with primers CTATCTACT GACCATTCTGGTATC and TCCTCTATAGTGTGAA ATTGAGGG created a 305 bp product that was cleaved by MspI into fragments of 207 and 98 bp. 11.3% of the samples were also genotyped for rs1343125 using SNPlex (Applied Biosystems, Foster City, CA, USA) -there was 100% concordance in genotypes between the two methodologies. This SNP was not in HWE in the NZ controls (Table 3a ; P ¼ 0.002); a possible reason for this is the possibility of a 63.1 kb deletion within MAGI3 encompassing rs1343125. 46 Allele frequencies at individual SNPs were compared between cases and controls using standard w 2 statistics, with Fisher's P-values reported. Alleles were tested for deviation from HWE using the SHEsis software platform. 47 COCAPHASE from UNPHASED 48 was used to implement the expectation-maximization (EM) algorithm for haplotype estimation, to perform haplotype association testing (unconditional logistic regression based on the maximum-likelihood frequency estimates from the EM algorithm) between cases and controls. Individual haplotypes were tested for association by grouping all others together, and haplotype-specific ORs generated in the same way. Ninety-five percent confidence intervals (CIs) were calculated from estimated haplotype 'counts' using Woolf's method; this is likely to underestimate the 95% CI owing to uncertain haplotype phase. Conditional analysis of one locus on the allele at a second locus, in LD with the first locus and known to be associated, was also performed in COCAPHASE; this implements the test of equality of ORs for haplotypes identical at conditioning loci.
